We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.96%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.6B
AUM Growth
+$1.15B
(+1.6%)
Cap. Flow
-$3.6B
Cap. Flow
% of AUM
-4.89%
Top 10 Holdings %
Top 10 Hldgs %
20.8%
Holding
3,102
New
50
Increased
790
Reduced
2,114
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$38.7M |
| 2 |
International Flavors & Fragrances
IFF
|
+$27.4M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$14.7M |
| 4 |
ConocoPhillips
COP
|
+$14.5M |
| 5 |
Royalty Pharma
RPRX
|
+$9.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$269M |
| 2 |
Microsoft
MSFT
|
+$172M |
| 3 |
Amazon
AMZN
|
+$114M |
| 4 |
Walt Disney
DIS
|
+$62.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$61.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.61% |
| 2 | Financials | 14.26% |
| 3 | Healthcare | 12.86% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 9.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
KRONOS Worldwide
KRO
$989M
| $603K | ﹤0.01% |
39,387
-400
| -1% | -$6K |
|
2402
Rocky Brands
RCKY
$369M
| $603K | ﹤0.01% |
11,150
-460
| -4% | -$18.1K |
|
2403
CNB Financial Corp
CCNE
$1.03B
| $602K | ﹤0.01% |
24,476
-740
| -3% | -$17.5K |
|
2404
Stoke Therapeutics
STOK
$2.11B
| $602K | ﹤0.01% |
15,507
-165
| -1% | -$9.39K |
|
2405
Hydrofarm Holdings
HYFM
$7.62M
| $601K | ﹤0.01% |
+997
| New | +$700K |
|
2406
Alerus Financial
ALRS
$828M
| $595K | ﹤0.01% |
19,979
-755
| -4% | -$22K |
|
|
KALV
2407
DELISTED
KalVista Pharmaceuticals
KALV
| $595K | ﹤0.01% |
23,177
+4,188
| +22% | +$110K |
|
2408
Akebia Therapeutics
AKBA
$252M
| $590K | ﹤0.01% |
174,241
-14,840
| -8% | -$53.5K |
|
|
TBCH
2409
Turtle Beach Corp
TBCH
$277M
| $589K | ﹤0.01% |
22,077
-535
| -2% | -$14.7K |
|
|
IGMS
2410
DELISTED
IGM Biosciences
IGMS
| $587K | ﹤0.01% |
7,655
-316
| -4% | -$28.8K |
|
2411
Amerant Bancorp
AMTB
$1.13B
| $586K | ﹤0.01% |
31,550
-1,145
| -4% | -$19.1K |
|
2412
BioXcel Therapeutics
BTAI
$27.8M
| $586K | ﹤0.01% |
848
-104
| -11% | -$83.7K |
|
|
BNFT
2413
DELISTED
Benefitfocus, Inc.
BNFT
| $586K | ﹤0.01% |
42,402
-2,290
| -5% | -$32.9K |
|
2414
Forestar Group
FOR
$1.51B
| $585K | ﹤0.01% |
25,132
-1,250
| -5% | -$28K |
|
2415
W&T Offshore
WTI
$518M
| $585K | ﹤0.01% |
163,087
-4,990
| -3% | -$15.5K |
|
2416
Oppenheimer Holdings
OPY
$1.2B
| $584K | ﹤0.01% |
14,580
-1,848
| -11% | -$68.5K |
|
2417
Arcutis Biotherapeutics
ARQT
$3.18B
| $582K | ﹤0.01% |
20,133
+45
| +0.2% | +$1.41K |
|
2418
VSE Corp
VSEC
$6.12B
| $579K | ﹤0.01% |
14,651
-80
| -0.5% | -$3.12K |
|
|
SCU
2419
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $578K | ﹤0.01% |
26,395
-1,345
| -5% | -$26.6K |
|
2420
Relmada Therapeutics
RLMD
$527M
| $577K | ﹤0.01% |
16,393
-735
| -4% | -$25.7K |
|
|
PAE
2421
DELISTED
PAE Incorporated Class A Common Stock
PAE
| $577K | ﹤0.01% |
63,956
-3,520
| -5% | -$31.4K |
|
|
BRY
2422
DELISTED
Berry Corp
BRY
| $576K | ﹤0.01% |
104,491
-8,112
| -7% | -$39.9K |
|
2423
National CineMedia
NCMI
$378M
| $575K | ﹤0.01% |
12,449
-900
| -7% | -$39.8K |
|
2424
ARS Pharmaceuticals
SPRY
$612M
| $575K | ﹤0.01% |
+13,189
| New | +$624K |
|
2425
Pulmonx
LUNG
$87.6M
| $574K | ﹤0.01% |
12,555
+918
| +8% | +$52.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2021 Portfolio in Review
As of Q1 2021, RhumbLine Advisers held 3,102 positions worth $73.6B, up 1.6% from $72.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
RhumbLine Advisers withdrew a net $3.6B in Q1 2021, closing 100 positions and reducing 2,114 holdings. Its most notable exit was Tiffany & Co., an estimated $26.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in NXP Semiconductors worth $42.7M.
- RhumbLine Advisers's largest Q1 2021 buy was NXP Semiconductors: 211,843 shares worth $42.7M.
- RhumbLine Advisers added most to International Flavors & Fragrances in Q1 2021, an estimated $27.4M increase.
- RhumbLine Advisers's biggest Q1 2021 reduction was Apple, cutting an estimated $269M.
- RhumbLine Advisers fully exited Tiffany & Co. in Q1 2021, selling an estimated $26.8M.
- RhumbLine Advisers's ten largest holdings make up 21% of its $73.6B portfolio in Q1 2021.
- RhumbLine Advisers opened 50 new positions and closed 100 in Q1 2021.
- RhumbLine Advisers's portfolio value rose 1.6% quarter-over-quarter to $73.6B.
Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.